Literature DB >> 22802421

Increased immune gene expression and immune cell infiltration in high-grade astrocytoma distinguish long-term from short-term survivors.

Andrew M Donson1, Diane K Birks, Stephanie A Schittone, Bette K Kleinschmidt-DeMasters, Derrick Y Sun, Molly F Hemenway, Michael H Handler, Allen E Waziri, Michael Wang, Nicholas K Foreman.   

Abstract

Survival in the majority of high-grade astrocytoma (HGA) patients is very poor, with only a rare population of long-term survivors. A better understanding of the biological factors associated with long-term survival in HGA would aid development of more effective therapy and survival prediction. Factors associated with long-term survival have not been extensively studied using unbiased genome-wide expression analyses. In the current study, gene expression microarray profiles of HGA from long-term survivors were interrogated for discovery of survival-associated biological factors. Ontology analyses revealed that increased expression of immune function-related genes was the predominant biological factor that positively correlated with longer survival. A notable T cell signature was present within this prognostic immune gene set. Using immune cell-specific gene classifiers, both T cell-associated and myeloid linage-associated genes were shown to be enriched in HGA from long-term versus short-term survivors. Association of immune function and cell-specific genes with survival was confirmed independently in a larger publicly available glioblastoma gene expression microarray data set. Histology was used to validate the results of microarray analyses in a larger cohort of long-term survivors of HGA. Multivariate analyses demonstrated that increased immune cell infiltration was a significant independent variable contributing to longer survival, as was Karnofsky/Lansky performance score. These data provide evidence of a prognostic anti-tumor adaptive immune response and rationale for future development of immunotherapy in HGA.

Entities:  

Mesh:

Year:  2012        PMID: 22802421      PMCID: PMC3411857          DOI: 10.4049/jimmunol.1103373

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  40 in total

1.  X-ray structures of the microglia/macrophage-specific protein Iba1 from human and mouse demonstrate novel molecular conformation change induced by calcium binding.

Authors:  Mitsugu Yamada; Keiko Ohsawa; Yoshinori Imai; Shinichi Kohsaka; Shigehiro Kamitori
Journal:  J Mol Biol       Date:  2006-09-15       Impact factor: 5.469

2.  The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses.

Authors:  S Farzana Hussain; David Yang; Dima Suki; Kenneth Aldape; Elizabeth Grimm; Amy B Heimberger
Journal:  Neuro Oncol       Date:  2006-06-14       Impact factor: 12.300

3.  Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme.

Authors:  Yu Liang; Maximilian Diehn; Nathan Watson; Andrew W Bollen; Ken D Aldape; M Kelly Nicholas; Kathleen R Lamborn; Mitchel S Berger; David Botstein; Patrick O Brown; Mark A Israel
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-12       Impact factor: 11.205

4.  Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.

Authors:  Jérôme Galon; Anne Costes; Fatima Sanchez-Cabo; Amos Kirilovsky; Bernhard Mlecnik; Christine Lagorce-Pagès; Marie Tosolini; Matthieu Camus; Anne Berger; Philippe Wind; Franck Zinzindohoué; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Franck Pagès
Journal:  Science       Date:  2006-09-29       Impact factor: 47.728

5.  Gene expression profiling and genetic markers in glioblastoma survival.

Authors:  Jeremy N Rich; Christopher Hans; Beatrix Jones; Edwin S Iversen; Roger E McLendon; B K Ahmed Rasheed; Adrian Dobra; Holly K Dressman; Darell D Bigner; Joseph R Nevins; Mike West
Journal:  Cancer Res       Date:  2005-05-15       Impact factor: 12.701

6.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

7.  MGMT gene silencing and benefit from temozolomide in glioblastoma.

Authors:  Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

Review 8.  Immune surveillance of tumors.

Authors:  Jeremy B Swann; Mark J Smyth
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

9.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.

Authors:  Heidi S Phillips; Samir Kharbanda; Ruihuan Chen; William F Forrest; Robert H Soriano; Thomas D Wu; Anjan Misra; Janice M Nigro; Howard Colman; Liliana Soroceanu; P Mickey Williams; Zora Modrusan; Burt G Feuerstein; Ken Aldape
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

10.  Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.

Authors:  Peter E Fecci; Duane A Mitchell; John F Whitesides; Weihua Xie; Allan H Friedman; Gary E Archer; James E Herndon; Darell D Bigner; Glenn Dranoff; John H Sampson
Journal:  Cancer Res       Date:  2006-03-15       Impact factor: 12.701

View more
  32 in total

1.  CSF1 Overexpression Promotes High-Grade Glioma Formation without Impacting the Polarization Status of Glioma-Associated Microglia and Macrophages.

Authors:  Ishani De; Megan D Steffen; Paul A Clark; Clayton J Patros; Emily Sokn; Stephanie M Bishop; Suzanne Litscher; Vilena I Maklakova; John S Kuo; Fausto J Rodriguez; Lara S Collier
Journal:  Cancer Res       Date:  2016-03-24       Impact factor: 12.701

Review 2.  Microenvironmental clues for glioma immunotherapy.

Authors:  Michael Platten; Katharina Ochs; Dieter Lemke; Christiane Opitz; Wolfgang Wick
Journal:  Curr Neurol Neurosci Rep       Date:  2014-04       Impact factor: 5.081

3.  Circulating T regulatory cells migration and phenotype in glioblastoma patients: an in vitro study.

Authors:  Chiara Vasco; Alessandra Canazza; Ambra Rizzo; Adele Mossa; Elena Corsini; Antonio Silvani; Laura Fariselli; Andrea Salmaggi; Emilio Ciusani
Journal:  J Neurooncol       Date:  2013-09-05       Impact factor: 4.130

Review 4.  Multidimensional communication in the microenvirons of glioblastoma.

Authors:  Marike L Broekman; Sybren L N Maas; Erik R Abels; Thorsten R Mempel; Anna M Krichevsky; Xandra O Breakefield
Journal:  Nat Rev Neurol       Date:  2018-08       Impact factor: 42.937

5.  Characterization of distinct immunophenotypes across pediatric brain tumor types.

Authors:  Andrea M Griesinger; Diane K Birks; Andrew M Donson; Vladimir Amani; Lindsey M Hoffman; Allen Waziri; Michael Wang; Michael H Handler; Nicholas K Foreman
Journal:  J Immunol       Date:  2013-09-27       Impact factor: 5.422

6.  NKG2D ligand expression in pediatric brain tumors.

Authors:  Kristen Haberthur; Kathryn Brennan; Virginia Hoglund; Stephanie Balcaitis; Harrison Chinn; Amira Davis; Shannon Kreuser; Conrad Winter; Sarah E S Leary; Gail H Deutsch; Richard G Ellenbogen; Courtney A Crane
Journal:  Cancer Biol Ther       Date:  2016-11-11       Impact factor: 4.742

7.  Leukocyte telomere length: a novel biomarker to predict the prognosis of glioma patients.

Authors:  Yibing Chen; Yousheng Wu; Xiaojun Huang; Ping Qu; Gang Li; Tianbo Jin; Jinliang Xing; Shiming He
Journal:  J Cancer Res Clin Oncol       Date:  2015-02-22       Impact factor: 4.553

8.  Immune heterogeneity and clinicopathologic characterization of IGFBP2 in 2447 glioma samples.

Authors:  Jinquan Cai; Qun Chen; Yuqiong Cui; Jiawei Dong; Meng Chen; Pengfei Wu; Chuanlu Jiang
Journal:  Oncoimmunology       Date:  2018-02-13       Impact factor: 8.110

9.  Differential gene methylation in paired glioblastomas suggests a role of immune response pathways in tumor progression.

Authors:  Agustí Alentorn; Alberto Durán-Peña; Andigoni Malousi; Yannick Marie; Karima Mokhtari; Marc Sanson; Khê Hoang-Xuan; Jean-Yves Delattre; Ahmed Idbaih; Charles Vecht
Journal:  J Neurooncol       Date:  2015-07-30       Impact factor: 4.130

Review 10.  Vaccine-based immunotherapy for glioblastoma.

Authors:  Alissa A Thomas; Jan L Fisher; Marc S Ernstoff; Camilo E Fadul
Journal:  CNS Oncol       Date:  2013-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.